Zenotech Laboratories last traded at ₹42.25 (2026-10-13). Over the past month the stock moved -5.4%, three months the stock moved -6.5%, year the stock moved -19.6%. Its closing range over 52 weeks is ₹35.39 – ₹53.49, with the latest close 21.0% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]
Business Overview:[1] ZTLL is a part of Sun Pharmaceuticals Industries Ltd. It does manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products
In the latest quarter (Jun 2026), Zenotech Laboratories reported sales of ₹10.62 crore (+10.2%) and net profit of ₹-0.46 crore (-146.5%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 10.62 | 0.86 | 8.10 | -0.46 | -0.08 |
| Mar 2026 | 9.89 | 0.17 | 1.72 | -3.15 | -0.52 |
| Dec 2025 | 12.86 | 4.27 | 33.20 | 1.93 | 0.32 |
| Sep 2025 | 11.23 | 2.29 | 20.39 | -0.84 | -0.14 |
| Jun 2025 | 9.64 | 2.46 | 25.52 | 0.99 | 0.16 |
| Mar 2025 | 12.13 | 4.47 | 36.85 | 1.23 | 0.20 |
| Dec 2024 | 11.24 | 3.87 | 34.43 | 1.69 | 0.28 |
| Sep 2024 | 9.77 | 2.41 | 24.67 | 1.35 | 0.22 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -15.3% | +2.7% | +33.2% | -2.7% | +14.9% | +14.4% | -18.5% | +10.2% |
| Operating profit growth | -56.3% | -26.6% | +60.8% | -28.3% | -5.0% | +10.3% | -96.2% | -65.0% |
| Net profit growth | -52.3% | -49.7% | +86.4% | -23.3% | -162.2% | +14.2% | -356.1% | -146.5% |
| EPS growth | -52.2% | -49.1% | +81.8% | -23.8% | -163.6% | +14.3% | -360.0% | -150.0% |
| OPM % | 24.7% | 34.4% | 36.9% | 25.5% | 20.4% | 33.2% | 1.7% | 8.1% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Zenotech Laboratories reported sales of ₹43.61 crore (+1.3%) and net profit of ₹-1.07 crore (-119.1%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 43.61 | 9.19 | 21.07 | -1.07 | -0.18 |
| Mar 2025 | 43.05 | 14.18 | 32.94 | 5.61 | 0.92 |
| Mar 2024 | 40.83 | 17.27 | 42.30 | 8.30 | 1.36 |
| Mar 2023 | 42.42 | 20.71 | 48.82 | 11.59 | 1.90 |
| Mar 2022 | 36.57 | 17.46 | 47.74 | 22.18 | 3.63 |
| Mar 2021 | 22.45 | 6.38 | 28.42 | -1.22 | -0.20 |
| Mar 2020 | 26.02 | 8.98 | 34.51 | 10.78 | 1.77 |
| Mar 2019 | 13.03 | -3.51 | -26.94 | -3.13 | -0.51 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +17.0% | +99.7% | -13.7% | +62.9% | +16.0% | -3.7% | +5.4% | +1.3% |
| Operating profit growth | – | – | -29.0% | +173.7% | +18.6% | -16.6% | -17.9% | -35.2% |
| Net profit growth | – | – | -111.3% | – | -47.7% | -28.4% | -32.4% | -119.1% |
| EPS growth | – | – | -111.3% | – | -47.7% | -28.4% | -32.4% | -119.6% |
| OPM % | -26.9% | 34.5% | 28.4% | 47.7% | 48.8% | 42.3% | 32.9% | 21.1% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Zenotech Laboratories.
Get Free AI Stock Analysis FREE →No recent news available for Zenotech Laboratories.
Zenotech Laboratories shares were last quoted at ₹42.25 (-1.9% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Zenotech Laboratories has a price-to-earnings (P/E) ratio of -102.80 and a price-to-book (P/B) ratio of 2.72. The industry P/E is 53.33.
The 52-week high of Zenotech Laboratories is ₹54.14 and the 52-week low is ₹33.55.
The market capitalisation of Zenotech Laboratories is about ₹257.24 crore.
In the latest quarter (Jun 2026), Zenotech Laboratories reported sales of ₹10.62 crore (+10.2%) and net profit of ₹-0.46 crore (-146.5%), compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Zenotech Laboratories has a 3-year ROE of 4.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 68.84% of Zenotech Laboratories.
Zenotech Laboratories belongs to the Pharmaceuticals & Drugs sector.